1. Home
  2. KRNY vs CTNM Comparison

KRNY vs CTNM Comparison

Compare KRNY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

HOLD

Current Price

$8.13

Market Cap

504.9M

Sector

Finance

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$12.90

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNY
CTNM
Founded
1884
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
504.9M
480.5M
IPO Year
2014
2024

Fundamental Metrics

Financial Performance
Metric
KRNY
CTNM
Price
$8.13
$12.90
Analyst Decision
Buy
Buy
Analyst Count
3
4
Target Price
$8.50
$19.00
AVG Volume (30 Days)
256.1K
253.2K
Earning Date
04-23-2026
05-13-2026
Dividend Yield
5.65%
N/A
EPS Growth
130.22
0.46
EPS
0.30
N/A
Revenue
$2,580,000.00
N/A
Revenue This Year
$3.89
N/A
Revenue Next Year
$17.52
N/A
P/E Ratio
$25.95
N/A
Revenue Growth
36.00
N/A
52 Week Low
$5.76
$3.35
52 Week High
$8.50
$16.33

Technical Indicators

Market Signals
Indicator
KRNY
CTNM
Relative Strength Index (RSI) 58.98 47.21
Support Level $7.77 $11.54
Resistance Level $8.33 $13.26
Average True Range (ATR) 0.22 0.58
MACD -0.00 -0.02
Stochastic Oscillator 83.64 51.94

Price Performance

Historical Comparison
KRNY
CTNM

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: